Tyme Inc. (TYME) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. DMART:IN
8. HUM
9. CSCO
10. KTOS

Go back to Tyme Inc. (TYME) Reports In-Line Q3 EPS

TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results

February 11, 2019 7:31 AM EST

TYMEs novel metabolic-based investigational cancer therapy, SM-88, demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients with advanced pancreatic cancerTYME is in discussions with the FDA regarding pivotal trial design for third-line pancreatic cancer based on preliminary results from the TYME-88-Panc Phase II trialTYME partners with the Pancreatic Cancer Action Networks (PanCAN) Precision Promise(SM) program to advance SM-88 pivotal paths for first- and second-line treatment in patients with pancreatic cancerInitiation of investigator-sponsored Phase II trial using SM-88 as monotherapy in patients with... More